Roche returns Maxy-alpha to Maxygen

MAXY said it and Roche (SWX:ROG) ended a 2003 deal to develop MAXY's Maxy-alpha (R7025) HBV and HCV program. In September, ROG voluntarily placed the program on hold after "an unexpected reduction of the pharmacodynamic and pharmacokinetic effects" was seen in a Phase Ia trial (See BioCentury Extra, Friday, Sep. 21, 2007). ...